Early Clinical Experience With Risperidone Long-Acting Injection

Taylor, David; Young, Corina; Mace, Shubhra; Patel, Maxine X.

doi:10.4088/jcp.v65n0808

Cited by 50 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations are consistent with increasing improvement in the primary outcome measure (BPRS total scores) over time with continued RLAI treatment. This fi nding contrasts with a recent study of 211 psychotic patients by Taylor et al, [60] in which 84 % discontinued RLAI within 3 years, 35.7 (SD = 10.5) mg every 2 weeks] for 6 months, Taylor and colleagues [61] had found that 51 % discontinued the treatment, although only 24 % showed a lack of effi cacy and the treatment was well-tolerated. These inconsistencies with our fi ndings at somewhat higher biweekly doses averaging 47 mg are unexplained, but may refl ect diff erences in case-selection.…”

Section: Discussioncontrasting

confidence: 70%

“…In fact, in the three Taylor et al trials [60,61,66] the study design allowed all prescribers to be informed that RLAI could be ordered for suitable patients with a DSM-IV diagnosis of schizophrenia or schizoaff ective disorder and known to be non-adherent to prescribed second-generation oral antipsychotics and intolerant of the adverse eff ects of conventional depot antipsichotics. In the study of 2004, Taylor et al [61] found that fi fty-one subjects (51 % ) discontinued RLAI within six months and the reason of discontinuation were: in 24 subjects (47 % ) the treatment was considered ineff ective (in 22 the treatment was considered ineffective by prescriber and there was an history of treatment resistance), in 18 (35 % ) patients refused to be treated and in 9 (18 % ) the treatment was not tolerated. Such treatment discontinuation rates are commonly encountered in long-term antipsychotic treatment [6,41,43] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

Girardi¹,

Serafini²,

Pompili³

et al. 2010

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

Girardi¹,

Serafini²,

Pompili³

et al. 2010

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…RLAI appeared to be generally well tolerated with only seven (12%) of the 58 patients discontinuing due to adverse effects. These findings are consistent with results from other naturalistic studies [13,14]. Pain during administration appeared to be a more common adverse effect with several anecdotal reports, which in three instances was severe enough to lead to discontinuation of treatment.…”

Section: Discussionsupporting

confidence: 93%

Experience with risperidone long-acting injection: results of a naturalistic observation study

Deslandes

Thomas

Faulconbridge

2007

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Typical antipsychotics are effective in the management of schizophrenia, but are associated with troublesome adverse effects which may lead to treatment discontinuation and relapse. Long-acting depot formulations of these drugs improve patient compliance, but do not reduce the incidence of adverse effects. There is evidence to suggest that newer atypical antipsychotic drugs have a reduced propensity to induce movement disorders and are associated with a modest reduction in relapse rates. The introduction of risperidone long-acting injection (RLAI) provided clinicians with the first long-acting formulation of an atypical antipsychotic. Objective. The aim of this study was to investigate the outcomes of patients from an acute mental health trust who received RLAI during the 18-month period following its licensing in the UK in order to examine measures of clinical effectiveness, and reasons for treatment discontinuation. Methods. Data were collected retrospectively from medical notes. Results. Fifty-nine patients were included in the study, and at the time of data collection 32 (54%) had discontinued treatment. The most common reason for discontinuation was lack of effectiveness, although all of the patients who discontinued due to lack of response were treatment resistant. RLAI appeared to be well tolerated, with only 12% of patients discontinuing due to adverse effects. Thirty-eight percent of the patients treated with RLAI showed a good response as measured by discharge from inpatient setting, and of the 22 outpatients at time of data collection, five had one re-hospitalisation during the study period. Conclusion. This study concludes that RLAI appears to be well tolerated, and shows some effectiveness in the treatment of schizophrenia, but may not be effective for patients who are treatment resistant.

show abstract

“…With the introduction of oral atypical antipsychotics, there has been initially a shift away from depot typicals to oral administration (Patel and David, 2005). Since the start of the 21 st century a long-acting injectable formulation of an atypical antipsychotic is available as a new additional treatment option (Taylor et al, 2004). Several advantages of long-acting injections compared with oral forms of medication were found in many studies for instance the transparency of non-adherence and the higher stability of the blood concentration that seems to be beneficial for the effect and side-effect profiles (Gerlach, 1994).…”

Section: Introductionmentioning

confidence: 99%

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Jaeger

Rössler

2010

Psychiatry Research

127

135

View full text Add to dashboard Cite

In many countries fewer than 20% of individuals with schizophrenia receive depot antipsychotic medication. Frequently stated reasons are psychiatrist's, patient's and relative's objections to depot treatment. This is the first study that directly compares the attitudes to depot antipsychotics of psychiatrists, patients and relatives. A semi-structured questionnaire about their attitudes to depot antipsychotics was completed by 255 participants (83 patients diagnosed with schizophrenic disorder, 81 psychiatrists in private practice and 91 relatives, not directly related to the patients). Patients were more negative towards depot injections than psychiatrists and relatives. They particularly fear to be constricted in their autonomy when treated with depot antipsychotics and that injections might be painful. About 67% of all patients in our sample did not receive information about depot antipsychotics by their psychiatrist. Less than 10% of psychiatrists offer depot treatment after a first psychotic episode. Psychiatrists use depot antipsychotics in a conservative way although they attribute positive traits to the method. Patients' negative attitudes might relate to the low level of information. To enhance the use of depot antipsychotics, information practices of psychiatrists should be improved. Patients should be informed about different applications forms already during early stages of the illness.

show abstract

Early Clinical Experience With Risperidone Long-Acting Injection

Cited by 50 publications

References 0 publications

Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

Experience with risperidone long-acting injection: results of a naturalistic observation study

Attitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatrists

Contact Info

Product

Resources

About